Your email has been successfully added to our mailing list.

×
-0.000579633340509721 -0.000932933662344288 -0.0035826860761031 -0.00683415310048627 -0.000160089208331243 -0.00144080287498131 -0.00330667019966989 -0.00385870195253632
Stock impact report

Augustine Therapeutics raises EUR 17M in Series A first closing [Seeking Alpha]

Eli Lilly and Company (LLY) 
Last eli lilly and company earnings: 4/23 06:25 am Check Earnings Report
US:NYSE Investor Relations: investor.lilly.com
Company Research Source: Seeking Alpha
The financing was led by Asabys Partners, with participation from Eli Lilly and Company and Charcot-Marie-Tooth Research Foundation. The proceeds from this first close will be used to advance Augustine's lead candidate, AGT100216, into a Phase 1/2 first-in-human clinical trial in 2025. The company also announced the appointment of Gerhard Koenig as executive chairman of its board. Recommended For You More Trending News In The News Most Active Trending Analysis Trending News Show less Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for LLY alerts
Opt-in for
LLY alerts

from News Quantified
Opt-in for
LLY alerts

from News Quantified